Key result
13N-ammonia PET detects myocardial fibrosis with ~84% sensitivity but underestimates overall extent versus CMR.
Why the study?
The influence of fibrosis transmurality and location on the diagnostic performance of PET MPI for detecting myocardial fibrosis remains unclear.
Does 13N-ammonia PET MPI accurately detect myocardial fibrosis compared to CMR in patients with suspected or known CAD or history of myocarditis?
Observational (n=100)
Does 13N-ammonia PET MPI accurately detect myocardial fibrosis compared to CMR in patients with suspected or known CAD or history of myocarditis?
13N-ammonia PET MPI has high per-patient sensitivity for detecting myocardial fibrosis but underestimates the overall extent compared to CMR, particularly for non-subendocardial and less transmural fibrosis.
Answers are grounded in this paper and cite their sources.
May support per-patient fibrosis detection by PET in CAD or myocarditis; leaves open extent quantification versus CMR.
BACKGROUND: The influence of fibrosis transmurality and location on the diagnostic performance of positron emission tomography (PET) myocardial perfusion imaging (MPI) for detecting myocardial fibrosis remains unclear. METHODS AND RESULTS: One hundred patients with suspected or known coronary artery disease (n = 50) or with a history of myocarditis (n = 50) underwent simultaneous cardiac magnetic resonance (CMR) and 13N-ammonia PET imaging on a hybrid positron emission tomography/magnetic resonance (PET/MR) device. CMR served as the reference with late gadolinium enhancement defining fibrosis of the left ventricular myocardium. PET MPI was assessed for fibrosis qualitatively (i.e. visually), semiquantitatively, and quantitatively (both threshold-based). From CMR, for every segment, the transmurality and location (subendocardial, midmyocardial, or subepicardial) of fibrosis were recorded. The sensitivity and specificity of qualitatively analyzed PET to detect fibrosis were 83.6% and 84.9% per patient and 52.9% and 96.4% per segment, respectively, outperforming the threshold-based semiquantitative and quantitative analyses. On a per-segment basis, the sensitivity of PET was increasing with transmurality and was dependent on location with higher sensitivities for subendocardial than subepicardial or midmyocardial fibrosis (P < .001). Overall median fibrosis extent, as depicted by PET, was significantly smaller than by CMR (2.0 [IQR 1.0-5.0] vs 3.0 [IQR 2.0-6.0] segments, P < .001). CONCLUSIONS: PET yields high sensitivity for the detection of left ventricular (LV) myocardial fibrosis of ischemic or inflammatory etiology on a per-patient basis. However, compared to CMR, the overall fibrosis extent is significantly underestimated because, on a segmental level, sensitivities are significantly lower for fibrosis with lower transmurality and those located subepicardial and midmyocardial, as compared to subendocardial.
No takes yet. Share an insight, caveat, or question.
Heiniger et al. (2025) conducted an observational in Suspected or known coronary artery disease or history of myocarditis (n=100). 13N-ammonia positron emission tomography (PET) imaging vs. Cardiac magnetic resonance (CMR) was evaluated on Overall median fibrosis extent (segments) (p=<.001). 13N-ammonia PET yielded high per-patient sensitivity for myocardial fibrosis but underestimated overall fibrosis extent compared to CMR.
Synapse has enriched 10 related papers. Consider them for comparative context: